Invitrogen to Acquire Antibody Maker Zymed for $60M

Invitrogen plans to acquire antibody manufacturer Zymed Laboratories for $60 million in cash, the company said this week.

Zymed, based in South San Francisco, Calif., offers immunoassay reagents for research and clinical diagnostics. The company has more than 2,000 antibodies and related products suitable for research in the areas of cancer, neurological diseases, and infectious disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.